



***Nanotechnology applications in hematological malignancies***

**(Essay)**

Submitted for the partial fulfillment of

**M.Sc. Degree in**

**CLINICAL and CHEMICAL PATHOLOGY**

**By**

***Ahmed Samir Abd El-Hamid***

**M.B.B.Ch. Cairo University**

Under supervision of

***Prof.Dr.Hala Gabr Metwally***

Professor of clinical and chemical pathology

Faculty of Medicine

Cairo University

***Dr.Basma Mustafa El-Gamal***

Assistant professor of clinical pathology

National Cancer Institute

Cairo University

**Faculty of medicine**

**Cairo University**

**2011**

## Acknowledgement

I wish to express my sincere gratitude and appreciation to Prof. **Dr.Hala Gabr Metwally**, Professor of clinical and chemical pathology, Faculty of Medicine, Cairo University for her inspiration, help and support before and during the progress of this work.

I am also so grateful and thankful to **Dr.Basma Mustafa El-Gamal**, Assistant professor of clinical pathology, National Cancer Institute, Cairo University for her support, advice, guidance and encouragement through this work.

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

"قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا هَا

عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ

الْحَكِيمُ"

البقرة : ٣٢

# Table of contents

Title	Page
<b>List of abbreviations</b>	II
<b>List of tables</b>	V
<b>List of figures</b>	VI
<b>Abstract</b>	VII
<b>Introduction</b>	1
<b>Chapter 1:An overview of nanotechnology and nanomedicine</b>	5
-Introduction	5
-History of nanotechnology	7
-The promise of nanotechnology	9
-Applications of nanotechnology	10
-Nanomedicine	13
-Benefits, Risks ,Ethical and Safety issues of nanotechnology and nanomedicine	22
-Future prospects of nanotechnology	28
<b>Chapter 2:Nanotechnology and cancer</b>	31
-An overview of cancer	31
-Nanotechnology and cancer	40
-Diagnostic applications of nanotechnology in cancer	42
-Nanotechnology and cancer therapy	56
<b>Chapter3 :Nanotechnology applications in hematological malignancies</b>	68
-Acute leukemias	68
-CML	81
-B-CLL	85
-Anaplastic large cell lymphoma	87
<b>Summary</b>	90
<b>References</b>	92
<b>Arabic summary</b>	—

# List of abbreviations

ADM	: Adriamycin
AL	: Acute leukemia
ALCL	: Anaplastic large cell lymphoma
ALK	: Anaplastic lymphoma kinase
ALL	: Acute lymphoid leukemia
AML	: Acute myeloid leukemia
APL	: Acute promyelocytic leukemia
ATRA	: All trans retinoic acid
AuNPs	: Gold nanoparticles
B-CLL	: B-Chronic lymphocytic leukemia
CML	: Chronic myeloid leukemia
CNTs	: Carbon nanotubes
CRI	: Cancer related inflammation
DNA	: Deoxyribonucleic acid
DNR	: Daunorubicin
EGFR	: Epidermal growth factor receptor
EPR	: Enhanced permeation and retention
FCM	: Flow cytometry
FDA	: Food and drug administration agency
FISH	: Fluorescent in situ hybridization
Flk-1	: Fetal liver kinase-1
Flt-1	: Fms-like tyrosine kinase-1
GMR	: Giant magneto resistance

GNPs	: Gold nanoparticles
GPI	: Glycosylphosphatidylinositol
HIV	: Human immune deficiency virus
HSCs	: Hematopoietic stem cells
IR	: Infra red
KDR	: Kinase domain receptor
LHRH	: Luteinizing hormone releasing hormone
LMWSC	: Low molecular weight water-soluble chitosan
mABs	: Monoclonal antibodies
MDR	: Multidrug resistance
MNPs	: Magnetic nanoparticles
MRD	: Minimal residual disease
MRI	: Magnetic resonance imaging
MWNT	: Multiwalled carbon nanotubes
NIR	: Near infra red
Nm	: Nanometere
NT	: Nanotechnology
PCR	: Polymerase chain reaction
PE	: Polyethelene glycol
QDs	: Quantum dots
RNA	: Ribonucleic acid
RSV	: Respiratory syncytial virus
RT-PCR	: Reverse transcriptase polymerase chain reaction
scFv	:Single chain antibody fragments

siRNAs	: Small interfering RNAs
SNPs	: Single nucleotide polymorphism
SPIONs	: Superparamagnetic iron oxide nanoparticles
SPR	: Surface plasmon resonance
SQUID	: Super conductor quantum interference devices
STM	: scanning tunneling microscope
Tet	: Tetrandrine
TK	: Tyrosine kinase
VEGF	: Vascular endothelial growth factor

# List of tables

NO.	Title	Page
1-1	Dimensions of various objects at nanoscale	6
1-2	Nanomedicine in the twenty first century	14
1-3	Classification of basic nanobiotechnologies	21
2-1	Strategies for drug delivery in cancer	58
2-2	Goals and classification of targeted nanoscale drug delivery system	61
2-3	Nano-scaled systems for systemic therapy	66
3-1	Methods for detection of MRD in Acute leukemia	74



# List of figures

No.	Title	Page
1-1	Dimensions of various objects at nanoscale	6
1-2	Schematic diagram showing Cantilevers	15
1-3	Quantum dots, , The color of a quantum dot depends on its size	16
1-4	Dendrimers can serve several functions at the same time	17
1-5	Molecular structure of fullerenes (buckyballs)	18
1-6	Nanoshells, Variety of core shell particles	19
1-7	Some single walled nanotubes with different chiralities	20
2-1	Evolving picture of medicine driving development of nanotechnology for investigation, diagnosis and treatment of cancer	37
2-2	Therapeutic targeting of the hallmarks cancer	40
2-3	Surface Plasmon resonance of Gold nanoparticles	50
2-4	Mechanism of nanoparticle drug delivery via passive and active targeting	61
2-5	Schematic diagram of nanoparticle accumulation in tumor tissue through EPR	63
2-6	Tumor activated prodrug delivery and targeting and self assembled nanoparticles with both diagnostic and therapeutic functions	64
2-7	Internalization of nanoparticles via receptor-mediated endocytosis	65
3-1	Representation of magnetic needle and sampling of spiked sample	76
3-2	Schematic representation of gold nanoparticles assay method for target RNA	83
3-3	Development of tumor cell type-selective and cancer gene specific nanocomplex for ALCL cells	89

# *Abstract*

## **Abstract**

The biological picture of cancer is rapidly advancing from models built from phenomenological descriptions to network models derived from systems biology, which can capture the evolving pathophysiology of the disease at the molecular level. The translation of this (still academic) picture into a clinically relevant framework can be enabling for the war on cancer. Nanotechnology can play a pivotal role, providing the technological power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today's explosion in knowledge. There are many interesting nanodevices being developed that have a potential to improve cancer detection, diagnosis, and treatment. Hematological malignancies represent a specific class of cancer that attracted special attention in the field of nanodiagnosis and treatment.

### **Key Words :**

Nanotechnology – Cancer - Hematological malignancies .

# ***Introduction***

## **Introduction**

Nanotechnology is the creation of useful materials, devices, and systems through the manipulation of matter on a miniscule scale. A nanometer is a billionth of a meter. Nanotechnology is being applied to almost every field imaginable, including electronics, magnetism, optics, information technology, materials development, and biomedicine (*U.S National Cancer Institute, 2011*).

Nanobiotechnology refers to materials and processes at the nanometer scale that are based on biological or biologically inspired molecules and nanotechnological devices used to monitor or control biological processes (*Ramsden, 2005*).

Cancer is the third leading cause of death (after heart disease and stroke) in developed countries (*Cai et al., 2008*). During dealing with cancer, three major problems are encountered; the first problem is related to diagnosis: detection of cancer at early stages is a critical step in improving cancer treatment. Currently; conventional detection of cancer is done by observing the physical growth changes in the organ by X-rays and/or CT scans and is confirmed by biopsy. However, the limitation of these methods is that they are not very sensitive and the detection is possible only after substantial growth of the cancerous cells (*Singh and Nehru, 2008*).

The second problem is related to therapy: conventional treatment options of cancer are surgery, radiation therapy and chemotherapy. However, all these methods have their own limitations (in surgery one loses the organ and cancer may appear again, in radiation therapy even the healthy cells get burnt, cancerous cells burning is not uniform and the

burnt part may become dead and non functional, in chemotherapy treatment is harmful to healthy cells, approach is gross and rarely successful if the cancer is in advanced stage (*Singh and Nehru, 2008*). The third problem is related to the follow up and detection of response after treatment.

Nanotechnology can find new solutions to all these problems, novel nanodevices are capable of one or more clinically important functions, including detecting cancer at its earliest stages, pinpointing its location within the body, delivering anticancer drugs specifically to malignant cells, and determining if these drugs are killing malignant cells (*U.S. department of health and human services, NIH, NCI, 2004*).

Hematological malignancies are the types of cancer that affect blood, bone marrow and lymph nodes. Historically; hematological malignancies have been most commonly divided by whether the malignancy is mainly located in the blood (leukemia) or in lymph nodes (lymphomas).

Conventional laboratory diagnostic methods for leukemia and lymphoma apply combinations of bone marrow and peripheral blood morphological and cytochemical analyses including karyotyping, immunophenotyping by flow cytometry or microarray and amplification of malignant cell mutations by PCR, as well as lymph node biopsy especially in lymphoma (*Arber and Cousar, 2009*).

However, all these methods have some limitations; PCR-based methods have proven to be highly sensitive diagnostic techniques for cellular recognition, but they are indirectly detecting cells by monitoring

RNA expression and require prolonged RNA isolation steps before analysis. In addition, the variable sensitivity of PCR can limit its effectiveness as a diagnostic technique and can lead to false-negative results, particularly with occult tumor cells where low-level signals are expected. Immunophenotypic analyses are also time-consuming and costly, and therefore, there is still a need to develop new technologies for rapid, economical cell recognition (*Herr et al., 2006*).

Nanotechnology, either alone or in combination with traditional diagnostic methods, tries to provide new sensitive, specific, reproducible and cheap methods for diagnosis of hematological malignancies.

Regarding treatment, nanotechnology offers the best promise among the various approaches for targeted delivery of drugs and genes to the tumor site and alleviation of the side effects of chemotherapeutic agents (*Robertson and Ferrari, 2007*).

Finally, current technologies used to examine bone marrow samples may fail to detect the presence of leukemia cells below 1% to 5% of total leukocytes after treatment, i.e., minimal residual disease. As a result, opportunities to intensify therapy may be overlooked, leading to relapsed disease, in these cases, the ability to reliably detect residual leukemia cells, when present below 5%, to monitor the efficacy of therapy is critical for improving care (*Jaetao et al., 2009*).

Nanotechnology can also improve sensitivity for detection of minimal residual disease compared with the current standard of care.